Drugmaker Sun Pharmaceutical Industries Ltd. has launched Favipiravir for the treatment of mild to moderate cases of Covid-19, at Rs 35 per tablet in India. Called FluGuard, the drug will be available in the market from this week.
Favipiravir is the only oral anti-viral treatment approved in India for potential treatment of patients with mild to moderate symptoms of the Covid-19 disease, said a statement by Sun Pharma. "We are launching FluGuard at an economical price to make it accessible to more and more patients thereby reducing their financial burden,” the company, India's largest drugmaker, said in an exchange filing on Tuesday. “This is in line with our continuous efforts to support India's pandemic response.”
-
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
India Could Gain If AI Trade Unwinds, US Midterms May Hurt Markets: Ramesh Damani -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI -
"I Am A Material Man In A Material World': Quantum Advisors' Ajit Dayal On NDTV Profit Ignite
The company said it will work closely with the government and the medical community to ensure availability of FluGuard (Favipiravir 200 mg) to patients across the country.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
As per last reported prices Sun has priced the drug cheaper than competitors. Cipla Ltd. will also launch Favipiravir in the country under the brand name Ciplenza in the first week of August priced at Rs 68 per tablet. Glenmark Pharmaceuticals Ltd., the first to launch the drug in India, has priced ‘FabiFlu' at Rs 75 per tablet (reduced from an earlier price of Rs 103 per tablet). Among others, Jenburkt Pharma launched Favipiravir at Rs 39 per tablet.
On Tuesday, Sun Pharma shares rose 1.67% to Rs 528.50 apiece on the BSE while the benchmark Sensex gained 2.03% to end the day at 37,687.91 points.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
